Search Results

Your search for Jocelyn Solis-Moreira, MS matches 2 pages

Showing 1 - 2

By Jocelyn Solis-Moreira, MS / June 2021 / EHA 2021 Virtual Congress

Phase II Study of Naratuximab Emtansine Plus Rituximab in DLBCL

Adding the antibody-drug conjugate naratuximab emtansine to rituximab resulted in favorable overall survival and complete response rates for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), with a manageable safety profile. These findings from a phase II study were...

leukemia

lymphoma

By Jocelyn Solis-Moreira, MS / June 2021 / EHA 2021 Virtual Congress

Ibrutinib/Venetoclax vs Chlorambucil/Obinutuzumab in Previously Untreated Older Patients With CLL/SLL

In a primary analysis of the phase III GLOW study, a once-daily, all-oral, fixed-duration dose of ibrutinib and venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) resulted in superior progression-free survival than treatment with chlorambucil and obinutuzumab. Arnon...

Nov

Today In Oncology

Search Results

Your search for Jocelyn Solis-Moreira, MS matches 2 pages

Phase II Study of Naratuximab Emtansine Plus Rituximab in DLBCL

Ibrutinib/Venetoclax vs Chlorambucil/Obinutuzumab in Previously Untreated Older Patients With CLL/SLL

Firefighters May Be Exposed to Chemicals Associated With Breast Cancer

FDA Grants Accelerated Approval to Zanidatamab-hrii for Previously Treated Unresectable or Metastatic HER2-Positive Biliary Tract Cancer

Novel EGFR Inhibitor Firmonertinib Shows Activity in Rare Subtype of NSCLC

Outcomes of Immune Checkpoint Inhibitor Treatment for Cancer in Black vs White Patients in the U.S. VHA System

Pooled Analysis of Long-Term Outcomes With Nivolumab With or Without Ipilimumab in Advanced Melanoma